Lewin G, Matus M, Basu A, Frebel K, Rohsbach SP, Safronenko A, Seidl MD, Stümpel F, Buchwalow I, König S, Engelhardt S, Lohse MJ, Schmitz W, Müller FU
Forschungsartikel (Zeitschrift) | Peer reviewedBACKGROUND: Chronic stimulation of the beta(1)-adrenoceptor (beta(1)AR) plays a crucial role in the pathogenesis of heart failure; however, underlying mechanisms remain to be elucidated. The regulation by transcription factors cAMP response element-binding protein (CREB) and cyclic AMP response element modulator (CREM) represents a fundamental mechanism of cyclic AMP-dependent gene control possibly implicated in beta(1)AR-mediated cardiac deterioration. METHODS AND RESULTS: We studied the role of CREM in beta(1)AR-mediated cardiac effects, comparing transgenic mice with heart-directed expression of beta(1)AR in the absence and presence of functional CREM. CREM inactivation protected from cardiomyocyte hypertrophy, fibrosis, and left ventricular dysfunction in beta(1)AR-overexpressing mice. Transcriptome and proteome analysis revealed a set of predicted CREB/CREM target genes including the cardiac ryanodine receptor, tropomyosin 1alpha, and cardiac alpha-actin as altered on the mRNA or protein level along with the improved phenotype in CREM-deficient beta(1)AR-transgenic hearts. CONCLUSIONS: The results imply the regulation of genes by CREM as an important mechanism of beta(1)AR-induced cardiac damage in mice.
König, Simone | Interdisziplinäres Zentrum für Klinische Forschung (IZKF) in der Med. Fakultät (IZKF) |
Müller, Frank Ulrich | Institut für Pharmakologie und Toxikologie |
Schmitz, Wilhelm | Institut für Pharmakologie und Toxikologie |
Seidl, Matthias | Institut für Pharmakologie und Toxikologie |
Stümpel, Frank | Institut für Pharmakologie und Toxikologie |